Table 1.
Application | Cancer Type | Imaging System | Contrast Agent | Clinical Status* |
---|---|---|---|---|
SLN mapping | Breast | Open | ICG11,52–56 | Clinical |
Melanoma | Open | ICG62,63, MMl69 | Clinical | |
Head and Neck | Open | ICG63,70, MMl27 | Clinical | |
Lung | VATS | ICG17,71 | Clinical | |
Esophagus | Open | ICG75,127 | Clinical | |
Stomach | Open | ICG74,128 | Clinical | |
Lap | ICG73,129 | Clinical | ||
Colorectal | Open | ICG9,130, HSA800 (ex vivo)59,60 | Clinical | |
Lap | ICG15,58,61 | Clinical | ||
Cervix | Open | ICG13,64,65 | Clinical | |
Vulvar | Open | ICG66–68 | Clinical | |
Endometrial | Lap | ICG72 | Clinical | |
Prostate | Lap/Rob | ICG131, MMI16 | Clinical | |
Penile | Open | MMI69 | Clinical | |
| ||||
Tumor imaging (in vivo) | Colorectal liver metastases | Open | ICG82,83,89 | Clinical |
Hepatocellular carcinoma | Open | ICG10,82 | Clinical | |
Lap | ICG132 | Preliminary | ||
Ovarian cancer metastases | Open | ICG93 | Preliminary | |
Breast cancer | Open | Bevacizumab-800CW113 | Preliminary | |
Insulinoma | Open | MB43 | Preclinical | |
Primary solitary tumor of the pancreas | Open | MB45 | Preliminary | |
Bladder cancer | Lap | 5-ALA97 | Clinical | |
Brain tumors | Open | 5-ALA,46–48, ICG91,92 | Clinical | |
| ||||
Tumor imaging (topical) | Bladder cancer | Cyst | 5-ALA99, HAL100 | Clinical |
Colon cancer | Endo | gGlu-HMRG122 | Preclinical | |
| ||||
Vital structures imaging | Bile ducts | Open | ICG133,134 | Clinical |
Lap | ICG101,135,136 | Clinical | ||
Ureters | Open | MB44 | Preliminary | |
Lymph Flow | Open | ICG55,102 | Clinical | |
Nerves | Open | Various35,118 | Preclinical | |
| ||||
Vascularization | Bowel anastomoses | Open | ICG104,105 | Clinical |
Lap | ICG106 | Clinical | ||
Reconstructive surgery | Open | ICG108–110 | Clinical |
Clinical = Multiple independent groups have reported successful application; Preliminary = Initial clinical application has been reported; Preclinical = Application has only been demonstrated in a preclinical setting.
Abbreviations: 5-ALA = 5-aminolevulinic acid; Bevacizumab-800CW = IRDye 800CW conjugated to Bevacizumab; gGlu-HMRG = g-glutamyl hydroxymethyl rhodamine green; ICG = indocyanine green; HAL = hexyl aminolevulinate; HSA800 = IRDye 800CW conjugated to human serum albumin; Lap = laparoscopic surgery; MB = methylene blue; MMI = multimodal imaging agent ICG-99mTechnetium-nanocolloid; Rob = robotic surgery; SLN = sentinel lymph node; VATS = video-assisted thoracoscopic surgery;